Skip header and navigation

3 records – page 1 of 1.

Open clinical uro-oncology trials in Canada.

https://arctichealth.org/en/permalink/ahliterature151561
Source
Can J Urol. 2009 Apr;16(2):4617-23
Publication Type
Article
Date
Apr-2009
Author
Eric Winquist
Mary J Mackenzie
George Rodrigues
Author Affiliation
London Health Sciences Centre, London, Ontario, Canada.
Source
Can J Urol. 2009 Apr;16(2):4617-23
Date
Apr-2009
Language
English
Publication Type
Article
Keywords
Antineoplastic Agents - therapeutic use
Canada
Humans
Randomized Controlled Trials as Topic
Urologic Neoplasms - drug therapy
PubMed ID
19364441 View in PubMed
Less detail

Re: Open clinical uro-oncology trials in Canada.

https://arctichealth.org/en/permalink/ahliterature160733
Source
Can J Urol. 2007 Oct;14(5):3723; author reply 3723
Publication Type
Article
Date
Oct-2007
Author
A. Morales
Source
Can J Urol. 2007 Oct;14(5):3723; author reply 3723
Date
Oct-2007
Language
English
Publication Type
Article
Keywords
Canada
Clinical Trials as Topic
Humans
Urologic Neoplasms - drug therapy
Notes
Comment On: Can J Urol. 2007 Aug;14(4):3662-717784993
PubMed ID
17949532 View in PubMed
Less detail

[Urological cancers: ECCO/ESMO congress 2011].

https://arctichealth.org/en/permalink/ahliterature124032
Source
Presse Med. 2012 Dec;41(12 Pt 1):1181-7
Publication Type
Conference/Meeting Material
Article
Date
Dec-2012
Author
Nabil Ismaili
Said Afqir
Rhizlane Belbaraka
Sanaa Elmajjaoui
Noureddine Benjaafar
Ali Tahri
Hassan Errihani
Author Affiliation
Centre régional d'oncologie, hôpital Hassan II, département d'oncologie médicale, Agadir 80000, Maroc. ismailinabil@yahoo.fr
Source
Presse Med. 2012 Dec;41(12 Pt 1):1181-7
Date
Dec-2012
Language
French
Publication Type
Conference/Meeting Material
Article
Keywords
Antineoplastic Agents - therapeutic use
Boronic Acids - therapeutic use
Humans
Hydroxamic Acids - therapeutic use
Medical Oncology
Pyrazines - therapeutic use
Societies, Medical
Sulfonamides - therapeutic use
Sweden
Urologic Neoplasms - drug therapy
Abstract
In the Congress of European Cancer Organisation (ECCO)/European Society for Medical Oncology (ESMO), which took place in Stockholm between 23 and 27 September 2011, urological cancers were the subject of various oral presentations and posters. A selection of the more innovative researches, likely to change the patients' management was performed. In prostate cancer, abiraterone acetate should be indicated in patients previously treated with docetaxel and sipuleucel-T in patients with asymptomatic or minimally symptomatic castrate-resistant prostate cancer. Alpharadine should be indicated in patients with symptomatic bone metastases and denosumab in non-metastatic prostate cancer patients with a high risk of developing bone metastases. In metastatic renal clear cell carcinoma, the genetic polymorphisms are predictive for efficacy of anti-angiogenic agents. Targeting both vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) pathways is a very promising strategy. In urothelial cancer, two molecules are promising, the belinostat and the bortezomib. Other news on penile cancer and testicular seminoma are discussed.
PubMed ID
22633546 View in PubMed
Less detail